-
1Academic Journal
المؤلفون: Arendt, C, De Leuw, P, Haberl, A, Kann, G, Wolf, T, Stephan, C, Schuettfort, G, Arcari, L, Vasquez, M, Albrecht, M, Escher, F, Vogl, T, Zeiher, A, Nagel, E, Puntmann, V
المصدر: European Heart Journal - Cardiovascular Imaging ; volume 22, issue Supplement_2 ; ISSN 2047-2404 2047-2412
مصطلحات موضوعية: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and imaging, General Medicine
-
2Academic Journal
المؤلفون: de Leuw, P., Stephan, C.
المساهمون: not funded
المصدر: Expert Opinion on Pharmacotherapy ; volume 19, issue 6, page 577-587 ; ISSN 1465-6566 1744-7666
-
3Academic Journal
المؤلفون: de Leuw, P, Stephan, C
المصدر: GMS Infectious Diseases; VOL: 5; DOC08 /20171128/
مصطلحات موضوعية: direct-acting antiviral, hepatitis C, HIV, NS3/4A protease inhibitor, ddc: 610
Relation: Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44( Suppl 1):S6-9. DOI:10.1016/j.jhep.2005.11.004; American Association for the study of liver diseases; Infectious Diseases Society of America. HCV GUIDIANCE: Recommendations for testing, managing, and treating hepatitis C. [cited 2017 Mar 3]. Available from: http://www.hcvguidelines.org/full-report-view; Full Prescribing Information for Olyiso(TM). FDA; 2013 [cited 2017 Feb 25]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf; Full Prescribing Information for VIEKIRA PAK(TM). FDA; 2014 [cited 2017 Feb 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf; Full prescribing information for ZEPATIER(TM). 2016 [cited 2017 Feb 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208261Orig1s000lbl.pdf; Arends JE, Lieveld FI, Boeijen LL, de Kanter CT, van Erpecum KJ, Salmon D, Hoepelman AI, Asselah T, Ustianowski A. Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms? J Hepatol. 2015 Nov;63(5):1254-62. DOI:10.1016/j.jhep.2015.06.034; Asselah T, Hezode C, Qaqish RB, Elkhashab T, Hassanein T, Papatheodoridis G, Alqahtanis S, Pilot-Matias T, Yu Y, Redman R, Mobashery N. High SVR rates in patients with genotype 4 chronic hepatitis C infection and compensated cirrhosis with ombitasvir/paritaprevir/ritonavir co-administered with ribavirin (AGATE-I). J Hepatol. 2016;64(2):S827. DOI:10.1016/S0168-8278(16)01618-4; Bae A, Sun SC, Qi X, Chen X, Ku K, Worth A, Wong KA, Harris J, Miller MD, Mo H. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother. 2010 Dec;54(12):5288-97. DOI:10.1128/AAC.00777-10; Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013 Feb;87(3):1544-53. DOI:10.1128/JVI.02294-12; Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017 Jul;66(1):27-36. DOI:10.1002/hep.29135; Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, Brinker A. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 2017 Jun;166(11):792-8. DOI:10.7326/M17-0377; Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06;376(22):2134-46. DOI:10.1056/NEJMoa1613512; Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Forns X. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. Clin Infect Dis. 2016 Jan 1;62(1):32-6. DOI:10.1093/cid/civ722; Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, Karlberg J, Lau G. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017 Jul;66(1):13-26. DOI:10.1002/hep.29109; Cohn J, Roberts T, Amorosa V, Lemoine M, Hill A. Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment. Curr Opin HIV AIDS. 2015 Sep;10(5):369-73. DOI:10.1097/COH.0000000000000180; Coilly A, Dumortier J, Botta-Fridlund D, Latournerie M, Leroy V, Pageaux GP, Agostini H, Giostra E, Moreno C, Roche B, Antonini TM, Guillaud O, Lebray P, Radenne S, Saouli AC, Calmus Y, Alric L, Debette-Gratien M, De Ledinghen V, Durand F, Duvoux C, Samuel D, Duclos-Vallée JC. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future? PLoS ONE. 2015;10(9):e0138091. DOI:10.1371/journal.pone.0138091; De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin TI, Dierynck I, Ceulemans H, Picchio G. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. J Viral Hepat. 2013 Jun;20(6):395-403. DOI:10.1111/jvh.12046; Deterding K, Spinner C, Schott E, Welzel T, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, von der Leyen H, von Witzendorff D, Manns MP, Wedemeyer H; HepNet Acute HCV/V Study Group. Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: the HEPNET acute HCV IV study. J Hepatol. 2016;64(2):S211. DOI:10.1016/S0168-8278(16)00177-X; Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PLoS ONE. 2015;10(8):e0134395. DOI:10.1371/journal.pone.0134395; Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology. 2015 Feb;148(2):355-66.e1. DOI:10.1053/j.gastro.2014.10.007; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017 Jan;66(1):153-94. DOI:10.1016/j.jhep.2016.09.001; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-98. DOI:10.1016/j.jhep.2017.03.021; Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, Shulman NS, Poordad F. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2016 Feb;64(2):301-7. DOI:10.1016/j.jhep.2015.10.005; Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr;370(17):1594-603. DOI:10.1056/NEJMoa1315722; Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May;370(21):1983-92. DOI:10.1056/NEJMoa1402338; Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Buti M. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015 Sep;63(3):564-72. DOI:10.1016/j.jhep.2015.04.009; Foster GR, Gane E, Asatryan A, Asselah T, Ruane PJ, Pol S, Poordad F, Stedman Ca, Dore G, Roberts SK, Kaita K, Vierling J, Vargas HE, Kort J, Lin CW, Liu R, NG T, Mensa F. Endurance-3: Safety and Efficacy of Glecaprevir/Pibrentasvir Compared To Sofosbuvir Plus Daclatasvir In Treatment-Nave Hcv Genotype 3-Infected Patients Without Cirrhosis. J Hepatol. 2017;66(1):S33. DOI:10.1016/S0168-8278(17)30326-4; Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep;347(13):975-82. DOI:10.1056/NEJMoa020047; Gamal N, Andreone P. Grazoprevir/elbasvir fixed-dose combination for hepatitis C. Drugs Today. 2016 Jul;52(7):377-85. DOI:10.1358/dot.2016.52.7.2510258; Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, Pol S, Leroy V, Persico M, Moreno C, Colombo M, Yoshida EM, Nelson DR, Collins C, Lei Y, Kosloski M, Mensa FJ. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017 10;377(15):1448-55. DOI:10.1056/NEJMoa1704053; Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016 Oct;151(4):651-659.e1. DOI:10.1053/j.gastro.2016.07.020; Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L, Baker R, Furrer H, Günthard HF, Freitas E, Humphreys I, Klenerman P, Mallal S, James I, Roberts S, Nolan D, Lucas M. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology. 2009 Apr;49(4):1069-82. DOI:10.1002/hep.22773; Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol. 1993 May;67(5):2832-43.; Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015 Jun;64(6):948-56. DOI:10.1136/gutjnl-2014-307498; Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med. 2015;7:51-70. DOI:10.2147/HMER.S55864; Houghton M, Weiner A, Han J, Kuo G, Choo QL. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology. 1991 Aug;14(2):381-8. DOI:10.1002/hep.1840140227; Howe AY, Black S, Curry S, Ludmerer SW, Liu R, Barnard RJ, Newhard W, Hwang PM, Nickle D, Gilbert C, Caro L, DiNubile MJ, Mobashery N. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis. 2014 Dec;59(12):1657-65. DOI:10.1093/cid/ciu696; Howe JA, Long J, Black S, Chase R, McMonagle P, Curry S, Thompson S, DiNubile MJ, Howe AY. Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin. Open Forum Infect Dis. 2014 Sep;1(2):ofu078. DOI:10.1093/ofid/ofu078; Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Bräu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. 2017 Jul;153(1):113-22. DOI:10.1053/j.gastro.2017.03.047; Kattakuzhy S, Levy R, Rosenthal E, Tang L, Wilson E, Kottilil S. Hepatitis C genotype 3 disease. Hepatol Int. 2016 Nov;10(6):861-70. DOI:10.1007/s12072-016-9748-z; Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell. 1996 Oct 18;87(2):343-55. DOI:10.1016/S0092-8674(00)81351-3; Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Cohen D, Podsadecki T, Pilot-Matias T, Collins C. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015 Sep;59(9):5445-54. DOI:10.1128/AAC.00998-15; Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Podsadecki T, Pilot-Matias T, Collins C. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r, ombitasvir- and dasabuvir-based regimens. J Hepatol. 2015 Apr;62(suppl 2):S220. DOI:10.1016/S0168-8278(15)30071-4; Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Pod-sadecki T, Pilot-Matias T, Collins C. Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. Hepatology. 2014 Oct;60(suppl 1):1134A-1135A.; Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-nave patients. Hepatology. 2008 Dec;48(6):1769-78. DOI:10.1002/hep.22549; Kwo P, Gane E, Peng C-Y, Pearlman B, Vireling J, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Robertson M, Wahl J, Barr E, Haber B. Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial. J Hepatol. 2015;62:S674. DOI:10.1016/S0168-8278(15)31088-6; Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, Schiff E, Davis M, Ruane P, Younes Z, Kalmeijer R, Sinha R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Witek J. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016 Aug;64(2):370-80. DOI:10.1002/hep.28467; Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014 Nov 15;384(9956):1756-65. DOI:10.1016/S0140-6736(14)61036-9; Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, Herring RW, Poleynard G, Sheikh A, Tobias H, Kugelmas M, Kalmeijer R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Sinha R, Witek J. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology. 2016 Aug;64(2):360-9. DOI:10.1002/hep.28422; Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015 Mar 21;385(9973):1075-86. DOI:10.1016/S0140-6736(14)61795-5; Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, Lovell S, Ng TI, Liu W, Campbell A, Lin CW, Yao B, Kort J. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection. Antimicrob Agents Chemother. 2015 Dec;60(3):1546-55. DOI:10.1128/AAC.02264-15; Lenz O, Vijgen L, Berke JM, Cummings MD, Fevery B, Peeters M, De Smedt G, Moreno C, Picchio G. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol. 2013 Mar;58(3):445-51. DOI:10.1016/j.jhep.2012.10.028; Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, Buelens A, Ceulemans H, Beumont M, Picchio G, De Meyer S. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol. 2015 May;62(5):1008-14. DOI:10.1016/j.jhep.2014.11.032; Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang J, Camus G, Zhang F, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng Cy, Chein RN, Chen PJ. Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Patients with Chronic Hepatitis C and Hepatitis B Coinfection: A Phase 3 Study in Taiwan. J Hepatol. 2017; 66(1):S56-57. DOI:10.1016/S0168-8278(17)30374-4; Lo Re V, Tate J, Kallan M, Lim J, Goetzet M, et al. Increased risk of hepatic decompensation and hepatocellular carcinoma in HIV/HCV-co-infected patients compared to HCV-mono-infected patients despite combination antiretroviral therapy. In: XIX International AIDS Conference; 2012 Jul 22-27; Washington, DC. WEAB0102.; Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S; HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014 Nov 1;384(9954):1597-605. DOI:10.1016/S0140-6736(14)61059-X; Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65. DOI:10.1016/S0140-6736(01)06102-5; McCauley JA, Rudd MT. Hepatitis C virus NS3/4a protease inhibitors. Curr Opin Pharmacol. 2016 Oct;30:84-92. DOI:10.1016/j.coph.2016.07.015; McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009 Aug;361(6):580-93. DOI:10.1056/NEJMoa0808010; McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, Levine S, Chaniewski S, Yu F, Barry D, Chen C, Lee MS, Mosure K, Sun LQ, Sinz M, Meanwell NA, Colonno RJ, Knipe J, Scola P. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012 Oct;56(10):5387-96. DOI:10.1128/AAC.01186-12; Mo H, Hedskog C, Lawitz E, Brainard DM, Yang J, Delaney W, Worth A, Miller MD. Antiviral response and resistance analysis of treatment-nave HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Res. 2017 Apr;140:151-7. DOI:10.1016/j.antiviral.2017.01.015; Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007 Jun;5(6):453-63. DOI:10.1038/nrmicro1645; Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012 Jun;56(6):1247-53. DOI:10.1016/j.jhep.2011.12.033; Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep;52(3):833-44. DOI:10.1002/hep.23744; Neukam K, Suàrez-Santamaria M, Rivero-Juárez A, Romero-Palacios A, Ortega E, de los Santos-Gil I, Cucurull J, Vera-Méndez F, Pineda JA. HIV coinfection impairs the response to DAA-based HCV therapy. J Hepatol. 2016;64(2):S219. DOI:10.1016/S0168-8278(16)00190-2; Ng T, Pilot-Matias T, Tripathi R, Schnell G, Reisch T, Beyer J, Dekhtyar T, Wang S, Mensa F, Kort J, Collins C. Analysis of HCV genotype 2 and 3 variants in patients treated with combination therapy of next generation HCV direct-acting antiviral agents ABT-493 and ABT-530. J Hepatol. 2016; 64:S409-410. DOI:10.1016/S0168-8278(16)00653-X; Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslén L, Duberg AS, Lennerstrand J. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res. 2013 Jul;99(1):12-7. DOI:10.1016/j.antiviral.2013.04.018; Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, Persson A, Huang SP, Hernandez D, Sheaffer AK, Scola P, Marbury T, Lawitz E, Goldwater R, Rodriguez-Torres M, Demicco M, Wright D, Charlton M, Kraft WK, Lopez-Talavera JC, Grasela DM. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr;56(4):1838-44. DOI:10.1128/AAC.05854-11; Petry AS, Fraser IP, O'Mara E, Van Dyck K, Nachbar RB, De Lepeleire IM, Robberechts M, Han L, Palcza J, Moiseev VS, Kobalava ZD, Wagner FD, Uhle M, Wagner JA. Safety and antiviral activity of MK-5172, a next generation HCV NS3/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology. 2011;54(4):531a.; Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, Reisch T, Irvin M, Hopkins T, Pithawalla R, Middleton T, Ng T, McDaniel K, Or YS, Menon R, Kempf D, Molla A, Collins C. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015 Feb;59(2):988-97. DOI:10.1128/AAC.04227-14; Pol S, Reddy KR, Baykal T, Hezode C. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology. 2014;60:1129.; Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Ley Y, NG TI, Pilot-Matias T, Kort J, Mensa F. Magellan-1, Part 2: Glecaprevir/Pibrentasvir for 12 Or 16 Weeks In Patients With Chronic Hcv Genotype 1 Or 4 And Prior Direct-Acting Antiviral Treatment Failure. In: The International Liver Congress (EASL); 2017 Apr 22; Amsterdam, The Netherlands.; Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014 May;370(21):1973-82. DOI:10.1056/NEJMoa1402869; Puoti M, Moioli MC, Travi G, Rossotti R. The burden of liver disease in human immunodeficiency virus-infected patients. Semin Liver Dis. 2012 May;32(2):103-13. DOI:10.1055/s-0032-1316473; Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van 't Klooster G, Lenz O, Aharchi F, Mariën K, Van Remoortere P, de Kock H, Broeckaert F, Meyvisch P, Van Beirendonck E, Simmen K, Verloes R. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010 Mar;138(3):913-21. DOI:10.1053/j.gastro.2009.10.033; Rockstroh J, Lutz T, Mauss S, Cordes C, Hillenbrand H, Moll A, Pfeiffer-Vornkahl H, Cornberg M, Manns MP, Baumgarten A; German Hepatitis C-Registry. SVR12 rates under DAA-based HCV therapy from the National German Cohort Study: Does HIV co-infection impair the response to DAA combination therapy? In: AASLD The Liver Meeting® 2016; 2016 Nov 11-15; Boston, MA. Abstract 907.; Rockstroh JK, Bhagani S, Hyland RH, Yun C, Dvory-Sobol H, Zheng W, Brainard DM, Ingiliz P, Lutz T, Boesecke C, Nelson M. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2017 May;2(5):347-53. DOI:10.1016/S2468-1253(17)30003-1; Rockstroh JK. Summary from AASLD 2015 for Hepatitis C Beyond 95% SVR cure rates: still room for improvement? In: 66th Annual Meeting of the American Association for the Study of Liver Diseases; 2015 Nov 13-17; Boston, MA. [cited 2015 Dec 29]. Available from: http://www.natap.org/2015/AASLD/AASLD_165.htm; Rodriguez-Torres M, Glass S, Hill J, Freilich B, Hassman D, Di Bisceglie AM, Taylor JG, Kirby BJ, Dvory-Sobol H, Yang JC, An D, Stamm LM, Brainard DM, Kim S, Krefetz D, Smith W, Marbury T, Lawitz E. GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. J Viral Hepat. 2016 Aug;23(8):614-22. DOI:10.1111/jvh.12527; Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016 Feb;64(2):486-504. DOI:10.1016/j.jhep.2015.09.011; Sarrazin C, Lathouwers E, Peeters M, Daems B, Buelens A, Witek J, Wyckmans Y, Fevery B, Verbinnen T, Ghys A, Schlag M, Baldini A, De Meyer S, Lenz O. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015 Apr;116:10-6. DOI:10.1016/j.antiviral.2015.01.003; Soumana DI, Kurt Yilmaz N, Ali A, Prachanronarong KL, Schiffer CA. Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease. J Am Chem Soc. 2016 Sep;138(36):11850-9. DOI:10.1021/jacs.6b06454; Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015 Mar 21;385(9973):1087-97. DOI:10.1016/S0140-6736(14)61793-1; Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, Huang Q, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7. DOI:10.1128/AAC.00324-12; Taylor J, Appleby T, Barauskas O, Chen X, Dvory-Sobol H, Gong R, Lee J, Nejati E, Schultz B, Wang Y, Yang C, Yu M, Zipfel S, Chan K. P0899: preclinical pro(LATIN SMALL LIGATURE FI)le of the pangenotypic HCV NS3/4A protease inhibitor GS-9857. J Hepatol. 2015 Apr;62(suppl 2): S681. DOI:10.1016/S0168-8278(15)31102-8; Tyson GL. Prevalence and determinants of hepatitis B co-infection among a United States Veterans Administration cohort with hepatitis C. Ann Arbor: The University of Texas School of Public Health, ProQuest Dissertations Publishing; 2012.; Vallet S, Viron F, Henquell C, Le Guillou-Guillemette H, Lagathu G, Abravanel F, Trimoulet P, Soussan P, Schvoerer E, Rosenberg A, Gouriou S, Colson P, Izopet J, Payan C; ANRS AC11 HCV Group. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther (Lond). 2011;16(7):1093-102. DOI:10.3851/IMP1900; Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007 Nov;147(10):677-84. DOI:10.7326/0003-4819-147-10-200711200-00003; Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005 Jul;11(7):791-6. DOI:10.1038/nm1268; Welzel TM, Zeuzem S, Dumas EO, Asselah T, Shaw D, Hazzan R, Forns X, Pilot-Mathias T, Lu W, Cohen DE, Feld J. GARNET: High SVR Rates Following 8-Week Treatment With Ombitasvir/ Paritaprevir/Ritonavir + Dasabuvir in Patients With HCV Genotype 1b Infection. In: EASL - AASLD Special Conference: New perspectives in hepatitis c virus infection - the roadmap for cure; 2016 Sep 23-24; Paris, France.; World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: WHO; 2014 [cited 2016 Oct 3]. Available from: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/; World Health Organization. Global report on access to hepatitis C treatment: Focus on overcoming barriers. Geneva: WHO; 2016 [cited 2017 Mar 5]. Available from: http://www.who.int/iris/handle/10665/250625; Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, Laursen AL, Luetkemeyer A, Nahass R, Pianko S, Zeuzem S, Jumes P, Huang HC, Butterton J, Robertson M, Wahl J, Barr E, Joeng HK, Martin E, Serfaty L; C-CREST Part C and C-SURGE Investigators. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. Hepatology. 2017 Jul 7. DOI:10.1002/hep.29358; Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015 Jul;163(1):1-13. DOI:10.7326/M15-0785; Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, Brown D, DiNubile M, Robertson M, Wahl J, Barr E, Butterton J. The phase 3 C-EDGE treatment-naive (TN) study of a 12-weeek oral regimen of grazoprevir (GZR, MK-5172)/elbasvir (EBR, MK-8742) in patients with chronic HCV genotype (GT) 1, 4 or 6 infection. J Hepatol. 2015;62:S213. DOI:10.1016/S0168-8278(15)30056-8; Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, Hueppe D, Zehnter E, Manns MP. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009 Feb;16(2):75-90. DOI:10.1111/j.1365-2893.2008.01012.x; http://dx.doi.org/10.3205/id000034; http://nbn-resolving.de/urn:nbn:de:0183-id0000345; http://www.egms.de/en/journals/id/2017-5/id000034.shtml
الاتاحة: https://doi.org/10.3205/id000034
http://nbn-resolving.de/urn:nbn:de:0183-id0000345
http://www.egms.de/en/journals/id/2017-5/id000034.shtml -
4Conference
المؤلفون: Arendt, C, Leithner, D, Haberl, A, Wolf, T, Stephan, C, Vogl, T, Nagel, E, de Leuw, P, Puntmann, V
المصدر: RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren ; 101. Deutscher Röntgenkongress und 9. Gemeinsamer Kongress der DRG und ÖRG ; ISSN 1438-9010
الاتاحة: http://dx.doi.org/10.1055/s-0040-1703153
http://www.thieme-connect.de/products/ejournals/html/10.1055/s-0040-1703153 -
5Conference
المؤلفون: Mücke, VT, Fitting, D, Dultz, G, de Leuw, P, Weiler, N, Mücke, MM, Hausmann, J, Welsch, C, Zeuzem, S, Bojunga, J, Friedrich-Rust, M
المصدر: Ultraschall in der Medizin - European Journal of Ultrasound ; Interdisziplinärer Kongress | Ultraschall 2019 – 43. Dreiländertreffen DEGUM | ÖGUM | SGUM ; ISSN 1438-8782
الاتاحة: http://dx.doi.org/10.1055/s-0039-1695809
http://www.thieme-connect.de/products/ejournals/html/10.1055/s-0039-1695809 -
6Academic Journal
المؤلفون: Schuettfort, G, Boekenkamp, L, Cabello, A, Cotter, AG, De Leuw, P, Doctor, J, Górgolas, M, Hamzah, L, Herrmann, E, Kann, G, Khaykin, P, Mallon, PW, Mena, A, Del Palacio Tamarit, M, Sabin, CA, Stephan, C, Wolf, T, Haberl, AE
المساهمون: Gilead Sciences
المصدر: HIV Medicine ; volume 22, issue 1, page 47-53 ; ISSN 1464-2662 1468-1293
-
7Academic Journal
المؤلفون: Arendt, C, De Leuw, P, Haberl, A, Stephan, C, Vasquez, M, Arcari, L, Zhou, H, Zainal, H, Albrecht, M, Vogl, T, Zeiher, A, Nagel, E, Puntmann, V
المصدر: European Heart Journal ; volume 41, issue Supplement_2 ; ISSN 0195-668X 1522-9645
مصطلحات موضوعية: Cardiology and Cardiovascular Medicine
-
8
المؤلفون: Jay B. Varkey, Morales A, Stephan Becker, Holger F. Rabenau, Aneesh K. Mehta, Stuart T. Nichol, Bruce S. Ribner, Vanessa Raabe, Timo Wolf, Gerrit Kann, Pierre E. Rollin, Stuart T. Brown, de Leuw P, Markus Eickmann, Colleen S. Kraft, Ute Ströher, Thomas Strecker, Kane Patel, John D. Klena, Christoph Stephan, Faber K, Sharon Vanairsdale, G. M. Lyon, Gundolf Schuettfort, Anita K. McElroy
المصدر: Clinical Infectious Diseases. 65:855-859
مصطلحات موضوعية: 0301 basic medicine, Microbiology (medical), Sexual transmission, viruses, Favipiravir, medicine.disease_cause, Article, Virus, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, law, medicine, 030212 general & internal medicine, Lassa fever, Polymerase chain reaction, business.industry, Ribavirin, virus diseases, medicine.disease, Virology, 030104 developmental biology, Infectious Diseases, Lassa virus, chemistry, Transaminitis, business
-
9Periodical
المؤلفون: Puntmann, Valentina O., Martin, Simon, Shchendrygina, Anastasia, Hoffmann, Jedrzej, Ka, Mame Madjiguène, Giokoglu, Eleni, Vanchin, Byambasuren, Holm, Niels, Karyou, Argyro, Laux, Gerald S., Arendt, Christophe, De Leuw, Philipp, Zacharowski, Kai, Khodamoradi, Yascha, Vehreschild, Maria J. G. T., Rohde, Gernot, Zeiher, Andreas M., Vogl, Thomas J., Schwenke, Carsten, Nagel, Eike
المصدر: Nature Medicine; October 2022, Vol. 28 Issue: 10 p2117-2123, 7p
-
10Academic Journal
المؤلفون: Schüttfort, G., Philipp, K., de Leuw, P., Herrmann, E., Kann, G., Khaykin, P., Stephan, C., Wolf, T., Haberl, A.
المصدر: Current HIV Research ; volume 17, issue 5, page 368-374 ; ISSN 1570-162X
-
11Academic Journal
المؤلفون: Kann, Gerrit, Wetzstein, Nils, Bielke, Hannah, Schuettfort, Gundolf, Haberl, Annette E., Wolf, Timo, Kuepper-Tetzel, Claus P., Wieters, Imke, Kessel, Johanna, de Leuw, Philipp, Bickel, Markus, Khaykin, Pavel, Stephan, Christoph
المصدر: Journal of Infection; Sep2021, Vol. 83 Issue 3, p347-353, 7p
مصطلحات موضوعية: HIV infection complications, HIV infections, RESEARCH, PNEUMOCYSTIS pneumonia, RESEARCH methodology, FUNGI, RETROSPECTIVE studies, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, IMMUNE reconstitution inflammatory syndrome
-
12Academic Journal
المؤلفون: de Leuw, Philipp, Arendt, Christophe T., Haberl, Annette E., Froadinadl, Daniel, Kann, Gerrit, Wolf, Timo, Stephan, Christoph, Schuettfort, Gundolf, Vasquez, Moises, Arcari, Luca, Zhou, Hui, Zainal, Hafisyatul, Gawor, Monika, Vidalakis, Eleftherios, Kolentinis, Michael, Albrecht, Moritz H., Escher, Felicitas, Vogl, Thomas J., Zeiher, Andreas M., Nagel, Eike
المصدر: JACC: Cardiovascular Imaging; Aug2021, Vol. 14 Issue 8, p1548-1557, 10p
-
13Academic Journal
المؤلفون: Krznaric, I, Bickel, M, Carganico, A, De Leuw, P, Haberl, A, Knecht, G, Koegl, C, Lauscher, P, Schüttfort, G, Stephan, C, Wolf, E, Wolf, T
المساهمون: Merck-Sharp Dome
المصدر: HIV Medicine ; volume 19, issue 9, page 662-667 ; ISSN 1464-2662 1468-1293
-
14Academic Journal
المؤلفون: Schuettfort, G, Boekenkamp, L, Cabello, A, Cotter, AG, De Leuw, P, Doctor, J, Górgolas, M, Hamzah, L, Herrmann, E, Kann, G, Khaykin, P, Mallon, PW, Mena, A, Del Palacio Tamarit, M, Sabin, CA, Stephan, C, Wolf, T, Haberl, AE
المصدر: HIV Medicine; Jan2021, Vol. 22 Issue 1, p47-53, 7p
-
15Academic Journal
المؤلفون: Schuettfort, G., de Leuw, P., Haberl, A., Stephan, C., Nguyen, M.
المصدر: Clinical Therapeutics ; volume 39, issue 8, page e46-e47 ; ISSN 0149-2918
-
16Academic Journal
المؤلفون: Schulze, K, Weismüller, T, Hübener, P, Zenouzi, R, Gotthardt, D, de Leuw, P, Bubenheim, M, Teufel, A, Zimmer, V, Lenzen, H, Reiter, F, Rust, C, Tharun, L, Quaas, A, Lammert, F, Galle, PR, Sarrazin, C, Manns, M, Lohse, AW, Schramm, C
المصدر: Zeitschrift für Gastroenterologie ; volume 52, issue 01 ; ISSN 0044-2771 1439-7803
الاتاحة: http://dx.doi.org/10.1055/s-0033-1361016
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0033-1361016 -
17Academic Journal
المؤلفون: Weismüller, T.J., Talwalkar, J.A., Ponsioen, C.Y., Gotthardt, D.N., Marschall, H.-U., Naess, S., Holm, K., Weersma, R.K., Lazaridis, K.N., Fevery, J., Trivedi, P.J., Schramm, C., Chazouilleres, O., Müller, T., Farkkila, M., Almer, S., Pereira, S., Mason, A.L., Floreani, A., Milkiewicz, P., Harley, H., Pares, A., de Vries, L., Manser, C., Gatselis, N., Berg, C., Lenzen, H., de Valle, M. Benito, Imam, M., Kirchner, G., de Leuw, P., Zimmer, V., Fabris, L., Braun, F., Hirschfield, G.M., Marzioni, M., Juran, B.D., Strassburg, C.P., Beuers, U., Manns, M.P., Schrumpf, E., Karlsen, T.H., Bergquist, A., Boberg, K.M.
المصدر: Journal of Hepatology ; volume 60, issue 1, page S3 ; ISSN 0168-8278
-
18Academic Journal
المؤلفون: Schulze, K, Weismüller, T, Hübener, P, Zenouzi, R, Gotthardt, D, de Leuw, P, Teufel, A, Zimmer, V, Reiter, FP, Lenzen, H, Rust, C, Tharun, L, Quaas, A, Lammert, F, Galle, PR, Sarrazin, C, Manns, M, Lohse, AW, Schramm, C
المصدر: Zeitschrift für Gastroenterologie ; volume 51, issue 08 ; ISSN 0044-2771 1439-7803
الاتاحة: http://dx.doi.org/10.1055/s-0033-1352797
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0033-1352797 -
19Academic Journal
المؤلفون: Horn, T, Pannicke, N, Dechene, A, Gotthardt, D, Kirchner, G, Reiter, FP, Herzer, K, Lenzen, H, Barg-Hock, H, Sterneck, M, de Leuw, P, Teufel, A, Zimmer, V, Lammert, F, Sarrazin, C, Spengler, U, Rust, C, Manns, MP, Strassburg, CP, Schramm, C, Weismüller, TJ
المصدر: Zeitschrift für Gastroenterologie ; volume 51, issue 08 ; ISSN 0044-2771 1439-7803
الاتاحة: http://dx.doi.org/10.1055/s-0033-1352815
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0033-1352815 -
20Academic Journal
المؤلفون: Horn, T., Pannicke, N., Dechene, A., Gotthardt, D., Kirchner, G., Reiter, F.P., Herzer, K., Lenzen, H., Barg-Hock, H., Sterneck, M., de Leuw, P., Teufel, A., Zimmer, V., Lammert, F., Sarrazin, C., Spengler, U., Rust, C., Manns, M.P., Strassburg, C.P., Schramm, C., Weismüller, T.J.
المصدر: Journal of Hepatology ; volume 58, page S42-S43 ; ISSN 0168-8278
Full Text Finder